Revelation Biosciences (NASDAQ:REVB) Receives “Sell (E)” Rating from Weiss Ratings

Weiss Ratings reissued their sell (e) rating on shares of Revelation Biosciences (NASDAQ:REVB) in a research note issued to investors on Tuesday,Weiss Ratings reports.

Separately, Wall Street Zen raised Revelation Biosciences to a “sell” rating in a report on Friday, June 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Revelation Biosciences Stock Performance

Shares of NASDAQ:REVB opened at $1.36 on Tuesday. Revelation Biosciences has a 52 week low of $1.28 and a 52 week high of $60.48. The company’s fifty day moving average is $2.10 and its 200-day moving average is $4.36. The company has a market capitalization of $3.18 million, a PE ratio of -0.02 and a beta of -0.12.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings results on Thursday, August 7th. The company reported ($7.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.46) by ($2.55). On average, analysts forecast that Revelation Biosciences will post -49.33 EPS for the current year.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.